Rubius Therapeutics to Participate in Jefferies Virtual Healthcare Conference

Rhea-AI Summary

Rubius Therapeutics, a clinical-stage biopharmaceutical company specializing in Red Cell Therapeutics, will have its CEO, Pablo J. Cagnoni, participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 4:00 p.m. EDT. The event will be webcast live and available for 90 days afterward. Rubius focuses on genetic engineering of red blood cells for innovative therapies aimed at treating cancer and autoimmune diseases. The company has received accolades for its workplace environment, being recognized among the top places to work in Massachusetts and Rhode Island.

CAMBRIDGE, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 4:00 p.m. EDT.

A live audio webcast will be available within the Investors & Media section of the Rubius Therapeutics website. An archived replay will be accessible for 90 days following the event.

About Rubius Therapeutics
Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. Rubius Therapeutics was named among the 2020 Top Places to Work in Massachusetts by the Boston Globe, and its manufacturing site was recently named 2021 Best Places to Work in Rhode Island by Providence Business News. For more information, visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us on Facebook.

Contacts:

Investors
Elhan Webb, CFA, VP Investor Relations
elhan.webb@rubiustx.com

Media
Marissa Hanify, Director, Corporate Communications
marissa.hanify@rubiustx.com

Dan Budwick, 1AB
+1 (973) 271-6085
dan@1abmedia.com

FAQ

What will Pablo J. Cagnoni discuss at the Jefferies Virtual Healthcare Conference on June 2, 2021?

Pablo J. Cagnoni, CEO of Rubius Therapeutics, will participate in a fireside chat discussing the company's advancements in Red Cell Therapeutics and its focus on treating cancer and autoimmune diseases.

How can I access the live audio webcast of the Rubius Therapeutics event?

The live audio webcast of the event on June 2, 2021, will be available in the Investors & Media section of the Rubius Therapeutics website.

What are Red Cell Therapeutics developed by Rubius Therapeutics?

Red Cell Therapeutics are genetically engineered red blood cells designed as innovative cellular medicines for treating various diseases, particularly cancer and autoimmune conditions.

How long will the archived replay of the Rubius Therapeutics event be available?

The archived replay of the conference will be accessible for 90 days following the live event on June 2, 2021.

What recognition has Rubius Therapeutics received for its workplace environment?

Rubius Therapeutics was named among the 2020 Top Places to Work in Massachusetts and its manufacturing site was awarded as one of the Best Places to Work in Rhode Island in 2021.